Threshold Pharmaceuticals (THLD) CEO Buys 20K Shares
More News related to THLD
- Threshold Pharmaceuticals Presents Interim Data From a Phase 1/2 Clinical Trial of TH-302 at Sarcoma Meeting
- Threshold Pharmaceuticals Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Threshold Pharma (THLD) Grants Exclusive Glufosfamide Rights to Elesion Pharma
- Threshold Pharmaceuticals Licenses Glufosfamide to Eleison Pharmaceuticals
Threshold Pharmaceuticals Inc. (Nasdaq: THLD) CEO Harold E. Selick bought 20,000 shares from 6/3-6/5 at prices from $1.48-$1.55, bringing his stake to 259,897 shares.
Threshold Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer.
Related Categories
Insider TradesStocks Mentioned
-0.31Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
